The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Open accessAbstract
Background Chimeric antigen receptor (CAR) modified T cells targeting CD19 have shown activity in case series of patients with acute and chronic lymphocytic leukaemia and B-cell lymphomas, but feasibility, toxicity, and response rates of consecutively enrolled patients treated with a consistent regimen and assessed on an intention-to-treat basis have not been reported. We aimed to define feasibility, toxicity, maximum tolerated dose, response rate, and biological correlates of response in children and young adults with refractory B-cell malignancies treated with CD19-CAR T cells. Methods This phase 1, dose-escalation trial consecutively enrolled children and young adults (aged 1-30 years) with relapsed or refractory acute lymphoblastic leukaemia or non-Hodgkin lymphoma. Autologous T cells were engineered via an 11-day manufacturing process to express a CD19-CAR incorporating an anti-CD19 single-chain variable fragment plus TCR zeta and CD28 signalling domains. All patients received fludarabine and cyclophosphamide before a single infusion of CD19-CAR T cells. Using a standard 3 + 3 design to establish the maximum tolerated dose, patients received either 1 × 10(6) CAR-transduced T cells per kg (dose 1), 3 × 10(6) CAR-transduced T cells per kg (dose 2), or the entire CAR T-cell product if sufficient numbers of cells to meet the assigned dose were not generated. After the dose-escalation phase, an expansion cohort was treated at the maximum tolerated dose. The trial is registered with ClinicalTrials.gov, number NCT01593696. Findings Between July 2, 2012, and June 20, 2014, 21 patients (including eight who had previously undergone allogeneic haematopoietic stem-cell transplantation) were enrolled and infused with CD19-CAR T cells. 19 received the prescribed dose of CD19-CAR T cells, whereas the assigned dose concentration could not be generated for two patients (90% feasible). All patients enrolled were assessed for response. The maximum tolerated dose was defined as 1 × 10(6) CD19-CAR T cells per kg. All toxicities were fully reversible, with the most severe being grade 4 cytokine release syndrome that occurred in three (14%) of 21 patients (95% CI 3·0-36·3). The most common non-haematological grade 3 adverse events were fever (nine [43%] of 21 patients), hypokalaemia (nine [43%] of 21 patients), fever and neutropenia (eight [38%] of 21 patients), and cytokine release syndrome (three [14%) of 21 patients). Interpretation CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukaemia. All toxicities were reversible and prolonged B-cell aplasia did not occur. Funding National Institutes of Health Intramural funds and St Baldrick's Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All approved CAR T-cell products are second-generation CARs that incorporate CD28 or CD137 (4-1BB) co-stimulatory signals, which are essential for eliciting effector and memory cell expansion and persistence and a clinically relevant immune response (9-15).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Further, most clinical protocols, and all the commercially approved therapies, have relied on viral vectors to deliver CAR transgenes into T cells (9-14,24-26).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“First, most CAR T cell trials to date have used autologous peripheral blood and apheresis as the main cell sources for manufacturing (9-18,21,22).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18921 · Cited by 4,694
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Self-citationMorgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564
Self-citationEfficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,417
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Cited by
Sorted by citations
Items 601–700 of 1,006
Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma
Zhang, J., Medeiros, L. J., & Young, K. H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00351 · Cited by 91
Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia
Guy, D. G., & Uy, G. L. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0472-8 · Cited by 92
Duan, D., Wang, K., Cheng, W., Feng, D., Liu, Y., He, Q., Xu, X., Wang, C., Zhao, S., Lv, L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.609421 · Cited by 90
Zhao, L., Li, S., Wei, X., Qi, X., Liu, D., Liu, L., Wen, F., Zhang, J., Wang, F., Liu, Z., et al. (2022) · Blood · doi:10.1182/blood.2022016243 · Cited by 92
Lussana, F., Intermesoli, T., Gianni, F., Boschini, C., Masciulli, A., Spinelli, O., Oldani, E., Tosi, M., Grassi, A., Parolini, M., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.07.021 · Cited by 88
Fludarabine and neurotoxicity in engineered T-cell therapy
Lowe, K. L., Mackall, C. L., Norry, E., Amado, R. G., Jakobsen, B. K., & Binder, G. K. (2018) · Gene Therapy · doi:10.1038/s41434-018-0019-6 · Cited by 89
Self-citationOelsner, S., Waldmann, A., Billmeier, A., Röder, J., Lindner, A., Ullrich, E., Marschalek, R., Dotti, G., Jung, G., Große‐Hovest, L., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32269 · Cited by 92
Emerging trends in immunotherapy for pediatric sarcomas
Dyson, K. A., Stover, B. D., Grippin, A., Méndez‐Gómez, H. R., Lagmay, J., Mitchell, D. A., & Sayour, E. J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0756-z · Cited by 91
Role of immunotherapy in Ewing sarcoma
Morales, E., Olson, M., Cardenas, F. I., Dahiya, S., Luetkens, T., & Atanackovic, D. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000653 · Cited by 87
Preclinical and clinical studies of CAR-NK-cell therapies for malignancies
Li, H., Song, W., Li, Z., & Zhang, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.992232 · Cited by 95
Neurological sequelae of cancer immunotherapies and targeted therapies
Wick, W., Hertenstein, A., & Platten, M. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30571-x · Cited by 87
CNS Endothelial Cell Activation Emerges as a Driver of CAR T Cell–Associated Neurotoxicity
Mackall, C. L., & Miklos, D. B. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1084 · Cited by 87
Self-citationCasucci, M., Falcone, L., Camisa, B., Norelli, M., Porcellini, S., Stornaiuolo, A., Ciceri, F., Traversari, C., Bordignon, C., Bonini, C., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00507 · Cited by 88
Updates on CAR T‐cell therapy in B‐cell malignancies
Jacoby, E., Shahani, S. A., & Shah, N. N. (2019) · Immunological Reviews · doi:10.1111/imr.12774 · Cited by 90
Self-citationRamanayake, S., Bilmon, I., Bishop, D. C., Dubosq, M., Blyth, E., Clancy, L. E., Gottlieb, D. J., & Micklethwaite, K. P. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2015.05.013 · Cited by 92
Shalabi, H., Wolters, P. L., Martin, S. C., Toledo‐Tamula, M. A., Roderick, M. C., Struemph, K. L., Kane, E., Yates, B., Delbrook, C., Mackall, C. L., et al. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000241 · Cited by 88
Self-citationBiology and clinical application of CAR T cells for B cell malignancies
Davila, M. L., & Sadelain, M. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2039-6 · Cited by 89
Kenderian, S. S., Porter, D. L., & Gill, S. I. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.09.002 · Cited by 86
Hucks, G., & Rheingold, S. R. (2019) · Blood Cancer Journal · doi:10.1038/s41408-018-0164-6 · Cited by 87
CAR‐T Cell Therapy in Cancer: Tribulations and Road Ahead
Zhang, Q., Ping, J., Huang, Z., Zhang, X., Zhou, J., Wang, G., Shaoyang, L., & Ma, J. (2020) · Journal of Immunology Research · doi:10.1155/2020/1924379 · Cited by 90
Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy
Lindo, L., Wilkinson, L., & Hay, K. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.618387 · Cited by 92
Cichocki, F. M., Goodridge, J. P., Bjordahl, R., Mahmood, S., Davis, Z., Gaidarova, S., Abujarour, R., Groff, B. C., Witty, A. D., Wang, H., et al. (2022) · Blood · doi:10.1182/blood.2021015184 · Cited by 87
Current status of chimeric antigen receptor therapy for haematological malignancies
Maude, S. L., & Barrett, D. M. (2015) · British Journal of Haematology · doi:10.1111/bjh.13792 · Cited by 87
Chakraborty, R., Sidana, S., Shah, G. L., Scordo, M., Hamilton, B. K., & Majhail, N. S. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.11.025 · Cited by 88
Klinger, M., Zugmaier, G., Nägele, V., Goebeler, M.-E., Brandl, C., Stelljes, M., Lassmann, H., von Stackelberg, A., Bargou, R. C., & Kufer, P. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1131 · Cited by 85
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
Zhang, Y., Li, C., Du, M., Jiang, H., Luo, W., Tang, L., Kang, Y. J., Xu, J. L., Wu, Z., Wang, X., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00822-w · Cited by 86
Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection
Zhukovsky, E. A., Morse, R. J., & Maus, M. V. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.02.006 · Cited by 85
Investigational CD33-targeted therapeutics for acute myeloid leukemia
Walter, R. B. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1452911 · Cited by 84
Traceless aptamer-mediated isolation of CD8+ T cells for chimeric antigen receptor T-cell therapy
Kacherovsky, N. A., Cardle, I. I., Cheng, E. L., Yu, J. L., Baldwin, M. L., Salipante, S. J., Jensen, M. C., & Pun, S. H. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0411-6 · Cited by 87
Xie, X., Hu, Y., Ye, T., Chen, Y., Zhou, L., Li, F., Xi, X., Wang, S., He, Y., Gao, X., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00624-6 · Cited by 84
Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment
Watanabe, N., McKenna, M. K., Shaw, A. R., & Suzuki, M. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.023 · Cited by 84
Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities
Dholaria, B., Bachmeier, C. A., & Locke, F. L. (2018) · BioDrugs · doi:10.1007/s40259-018-0324-z · Cited by 83
Gutiérrez, C., McEvoy, C. A., Munshi, L., Stephens, R. S., Detsky, M. E., Nates, J. L., & Pastores, S. M. (2019) · Critical Care Medicine · doi:10.1097/ccm.0000000000004087 · Cited by 82
NF-κB in the New Era of Cancer Therapy.
Eluard, B., Thieblemont, C., & Baud, V. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.04.003 · Cited by 74
Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy
Tedesco, V. E., & Mohan, C. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001249 · Cited by 84
CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia
Bonifant, C. L., Szöőr, Á., Torres, D., Joseph, N. P., Velasquez, M. P., Iwahori, K., Gaikwad, A. S., Nguyen, P., Arber, C., Song, X., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.116 · Cited by 84
Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors
Suerth, J. D., Morgan, M. A., Kloeß, S., Heckl, D., Neudörfl, C., Falk, C. S., Koehl, U., & Schambach, A. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1327-6 · Cited by 82
Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies
Fishman, J. A., Hogan, J. I., & Maus, M. V. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1025 · Cited by 83
Nie, Y., Lu, W., Chen, D., Tu, H., Guo, Z., Zhou, X., Li, M., Tu, S., & Li, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-00197-1 · Cited by 85
Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors
Donnadieu, E., Dupré, L., Pinho, L. G., & Cotta-de-Almeida, V. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.1mr0520-746r · Cited by 85
MAGE-A antigens as targets for cancer immunotherapy
Schooten, E., Maggio, A. D., Henegouwen, P. M. P. V. B. E., & Kijanka, M. M. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.009 · Cited by 86
Rangan, S., Schulze, H. G., Vardaki, M. Z., Blades, M. W., Piret, J. M., & Turner, R. F. B. (2020) · The Analyst · doi:10.1039/c9an01811e · Cited by 82
Rewired signaling network in T cells expressing the chimeric antigen receptor (CAR)
Dong, R., Libby, K. A., Blaeschke, F., Fuchs, W., Marson, A., Vale, R. D., & Su, X. (2020) · The EMBO Journal · doi:10.15252/embj.2020104730 · Cited by 85
Glycoengineering of NK Cells with Glycan Ligands of CD22 and Selectins for B‐Cell Lymphoma Therapy
Hong, S., Yu, C., Wang, P., Shi, Y., Cao, W., Cheng, B., Chapla, D. G., Ma, Y., Li, J., Rodrigues, E., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202005934 · Cited by 80
Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma
Jiang, W., Li, T., Guo, J., Wang, J., Jia, L., Xiao Hua, S. H. I., Yang, T., Jiao, R., Wei, X. C., Feng, Z., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.546586 · Cited by 80
Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells
Stroncek, D. F., Lee, D. W., Ren, J., Sabatino, M., Highfill, S., Khuu, H., Shah, N. N., Kaplan, R. N., Fry, T. J., & Mackall, C. L. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1160-5 · Cited by 80
Self-citationCancer Precision Medicine: From Cancer Screening to Drug Selection and Personalized Immunotherapy
Deng, X., & Nakamura, Y. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.013 · Cited by 82
Therapeutic potential of CRISPR/Cas9 gene editing in engineered T‐cell therapy
Gao, Q., Dong, X., Xu, Q., Zhu, L., Wang, F., Hou, Y., & Chao, C. (2019) · Cancer Medicine · doi:10.1002/cam4.2257 · Cited by 85
Opportunities and Challenges in Drug Development for Pediatric Cancers
Laetsch, T. W., DuBois, S. G., Bender, J. G., Macy, M. E., & Moreno, L. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0779 · Cited by 85
Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies
Li, Y.-R., Halladay, T., & Yang, L. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-00998-8 · Cited by 85
Hombach, A. A., Görgens, A., Chmielewski, M. M., Murke, F., Kimpel, J., Giebel, B., & Abken, H. (2016) · Molecular Therapy · doi:10.1038/mt.2016.82 · Cited by 81
Redeker, A., & Arens, R. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00345 · Cited by 79
Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment
Wang, Z., Guo, Y., & Han, W. (2017) · Protein & Cell · doi:10.1007/s13238-017-0400-z · Cited by 83
Keyel, M. E., & Reynolds, C. P. (2018) · Biologics · doi:10.2147/btt.s114530 · Cited by 82
Safety and Tolerability of Adoptive Cell Therapy in Cancer
Wolf, B., Zimmermann, S., Arber, C., Irving, M. B., Trueb, L., & Coukos, G. (2019) · Drug Safety · doi:10.1007/s40264-018-0779-3 · Cited by 79
Byrne, M. T., Oluwole, O. O., Savani, B. N., Majhail, N. S., Hill, B. T., & Locke, F. L. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.06.036 · Cited by 81
Fabrizio, V. A., Phillips, C. L., Lane, A., Baggott, C., Prabhu, S., Egeler, E. L., Mavroukakis, S. A., Pacenta, H. L., Rossoff, J. E., Stefanski, H. E., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005564 · Cited by 79
Self-citationSynthetic biology in cell-based cancer immunotherapy
Chakravarti, D., & Wong, W. W. (2015) · Trends in biotechnology · doi:10.1016/j.tibtech.2015.05.001 · Cited by 80
CD19‐Targeted chimeric antigen receptor‐modified T‐cell immunotherapy for B‐cell malignancies
Turtle, C. J., Riddell, S., & Maloney, D. G. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.392 · Cited by 79
A compound chimeric antigen receptor strategy for targeting multiple myeloma
Chen, K. H., Wada, M., Pinz, K. G., Liu, H., Shuai, X., Chen, X., Yan, L. E., Petrov, J. C., Salman, H., Senzel, L. B., et al. (2017) · Leukemia · doi:10.1038/leu.2017.302 · Cited by 78
Qin, J., Johnstone, T. G., Baturevych, A., Hause, R. J., Ragan, S. P., Clouser, C. R., Jones, J. C., Ponce, R. A., Krejsa, C. M., Salmon, R. A., et al. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000307 · Cited by 79
Qin, H., Yang, L., Chukinas, J. A., Shah, N. N., Tarun, S., Pouzolles, M., Chien, C. D., Niswander, L. M., Welch, A. R., Taylor, N. N., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003149 · Cited by 78
Self-citationExploring CAR-T Cell Therapy Side Effects: Mechanisms and Management Strategies
Zhang, Y., Qin, D., Shou, A., Liu, Y., Wang, Y., & Zhou, L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196124 · Cited by 82
A novel method to generate T-cell receptor–deficient chimeric antigen receptor T cells
Kamiya, T., Wong, D., Png, Y. T., & Campana, D. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017012823 · Cited by 80
Rössig, C., Pulè, M. A., Altvater, B., Saïagh, S., Wright, G. P., Ghorashian, S., Clifton‐Hadley, L., Champion, K. M., Sattar, Z., Popova, B., et al. (2017) · Leukemia · doi:10.1038/leu.2017.39 · Cited by 78
Wei, G., Ding, L., Wang, J., Hu, Y., & Huang, H. (2017) · Experimental Hematology and Oncology · doi:10.1186/s40164-017-0070-9 · Cited by 78
Cardiotoxicity of T-Cell Antineoplastic Therapies
Ganatra, S., Dani, S. S., Yang, E. H., Zaha, V. G., & Nohria, A. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.07.014 · Cited by 78
Trial Watch: Adoptively transferred cells for anticancer immunotherapy
Fournier, C., Martin, F., Zitvogel, L., Kroemer, G., Galluzzi, L., & Apétoh, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1363139 · Cited by 79
Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer
Hillerdal, V., & Essand, M. (2015) · BioDrugs · doi:10.1007/s40259-015-0122-9 · Cited by 75
Prognostic factors and treatment of pediatric acute lymphoblastic leukemia
Lee, J. W., & Cho, B. (2017) · Korean Journal of Pediatrics · doi:10.3345/kjp.2017.60.5.129 · Cited by 89
Geyer, M. B., Rivière, I., Sénéchal, B., Wang, X., Wang, Y., Purdon, T. J., Hsu, M., Devlin, S. M., Halton, E. F., Lamanna, N., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.018 · Cited by 76
Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells
Dwivedi, A., Karulkar, A., Ghosh, S., Rafiq, A., & Purwar, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03180 · Cited by 78
CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics
Ghosh, D., Venkataramani, P., Nandi, S., & Bhattacharjee, S. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0726-0 · Cited by 83
Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma
Wang, Y., Yu, W., Zhu, J., Wang, J., Xia, K., Liang, C., & Tao, H. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1147-6 · Cited by 75
Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days
Mikkilineni, L., Yates, B., Steinberg, S. M., Shahani, S. A., Molina, J. C., Palmore, T., Lee, D. W., Kaplan, R. N., Mackall, C. L., Fry, T. J., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004896 · Cited by 75
Self-citationHumanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies
Mhaidly, R., & Verhoeyen, E. (2020) · Cancers · doi:10.3390/cancers12071915 · Cited by 76
Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients
Ishii, K., Pouzolles, M., Chien, C. D., Erwin-Cohen, R. A., Kohler, M. E., Qin, H., Lei, H., Kuhn, S. A., Ombrello, A. K., Dulau‐Florea, A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci130059 · Cited by 77
Self-citationThe emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy
Fabian, K. P., & Hodge, J. W. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.10.001 · Cited by 77
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don’t Forget the Fuel
Irving, M. B., de Silly, R. V., Scholten, K. B. J., Dilek, N., & Coukos, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00267 · Cited by 76
Krishnamoorthy, S., Ghobadi, A., Santos, R. D., Schilling, J. D., Malone, A. F., Murad, H., Bartlett, N. L., & Alhamad, T. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16367 · Cited by 75
Santoro, N., Ruggeri, A., Labopin, M., Bacigalupo, A. P., Ciceri, F., Gülbaş, Z., Huang, H., Afanasyev, B. V., Arcese, W., Wu, D., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0480-5 · Cited by 75
Programmed cell death protein 1 activation preferentially inhibits CD28.CAR–T cells
Zolov, S. N., Rietberg, S. P., & Bonifant, C. L. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2018.07.005 · Cited by 73
Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells
Wang, X., Jasinski, D. L., Medina, J. L., Spencer, D. M., Foster, A. E., & Bayle, J. H. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001510 · Cited by 75
Intracellular Delivery of mRNA in Adherent and Suspension Cells by Vapor Nanobubble Photoporation
Raes, L., Stremersch, S., Fraire, J. C., Brans, T., Goetgeluk, G., Munter, S. D., Hoecke, L. V., Verbeke, R., Hoeck, J. V., Xiong, R., et al. (2020) · Nano-Micro Letters · doi:10.1007/s40820-020-00523-0 · Cited by 76
An, F., Wang, H., Liu, Z., Wu, F., Zhang, J., Tao, Q., Li, Y., Shen, Y., Ruan, Y., Zhang, Q., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19774-x · Cited by 79
Cardiotoxicities of novel cancer immunotherapies
Stein-Merlob, A. F., Rothberg, M. V., Ribas, A., & Yang, E. H. (2021) · Heart · doi:10.1136/heartjnl-2020-318083 · Cited by 73
Smart CARs engineered for cancer immunotherapy
Priceman, S. J., Forman, S. J., & Brown, C. E. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000232 · Cited by 70
Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors
Torikai, H., & Cooper, L. J. N. (2016) · Molecular Therapy · doi:10.1038/mt.2016.106 · Cited by 74
Hill, J. A., Krantz, E. M., Hay, K. A., Dasgupta, S., Stevens‐Ayers, T., Ignacio, R. B., Bar, M., Maalouf, J., Cherian, S., Chen, X., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000717 · Cited by 75
Building blocks for institutional preparation of CTL019 delivery
McGuirk, J. P., Waller, E. K., Qayed, M. D., Abhyankar, S., Ericson, S. G., Holman, P., Keir, C. H., & Myers, G. D. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.06.001 · Cited by 75
Li, S., Zhang, J., Wang, M., Fu, G., Li, Y., Li, P., Xiong, Z., Qin, D., Zhang, R., Tian, X., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15195 · Cited by 73
Suryadevara, C. M., Desai, R. R., Farber, S. H., Choi, B. D., Swartz, A. M., Shen, S. H., Gedeon, P. C., Snyder, D. J., Herndon, J. E., Healy, P. N., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1211 · Cited by 75
Beyond the storm — subacute toxicities and late effects in children receiving CAR T cells
Shalabi, H., Gust, J., Taraseviciute, A., Wolters, P. L., Leahy, A. B., Sandi, C., Laetsch, T. W., Wiener, L. S., Gardner, R. A., Nussenblatt, V. R., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00456-y · Cited by 74
Self-citationDirecting CAR T cells towards the tumor vasculature for the treatment of solid tumors
Akbari, P., Katsarou, A., Daghighian, R., van Mil, L. W. H. G., Huijbers, E. J. M., Griffioen, A. W., & B, J. R. V. B. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188701 · Cited by 72
Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment
Yang, L., Ning, Q., & Tang, S. (2022) · Journal of Immunology Research · doi:10.1155/2022/8052212 · Cited by 78
A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021
Miao, L., Zhang, J., Zhang, Z., Wang, S., Tang, F., Teng, M., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.840956 · Cited by 76
Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?
Kozani, P. S., Kozani, P. S., Najafabadi, M. A., Yousefi, F., Mirarefin, S. M. J., & Rahbarizadeh, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.795164 · Cited by 75
Schultz, L. M., Eaton, A. A., Baggott, C., Rossoff, J. E., Prabhu, S., Keating, A. K., Krupski, C., Pacenta, H. L., Phillips, C. L., Talano, J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01076 · Cited by 76
Self-citationLee, P., Bhansali, R. S., Izraeli, S., Hijiya, N., & Crispino, J. D. (2016) · Leukemia · doi:10.1038/leu.2016.164 · Cited by 73
T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities
Wang, Z., Li, B., Ren, Y., & Ye, Z. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00353 · Cited by 73
Metadata
- Authors
- Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., Steinberg, S. M., Stroncek, D., Tschernia, N., Yuan, C., Zhang, H., Zhang, L., Rosenberg, S. A., Wayne, A. S., & Mackall, C. L.
- Affiliations
- National Institutes of Health (US)
- National Cancer Institute (US)
- University of Nevada, Reno (US)
- University of Southern California (US)
- Corresponding author
- Mackall, Crystal L
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 385
- Issue
- 9967
- Pages
- 517-528
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC7065359
- OpenAlex
- W2129702476
- Cited by
- 2,898
- References
- 37
- Citations by year
- 2026: 86 · 2025: 154 · 2024: 175 · 2023: 217 · 2022: 275 · 2021: 311 · 2020: 350 · 2019: 317 · 2018: 315 · 2017: 314 · 2016: 232 · 2015: 134
- FWCI
- 103.68
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- St. Baldrick's Foundation
- Entertainment Industry Foundation
- National Institutes of Health
- National Cancer Institute (Z01BC011072, Z01BC010566, Z01BC011024)
- National Institute of Allergy and Infectious Diseases
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CD19 chimeric antigen receptor, CAR T-cell therapy, acute lymphoblastic leukemia, non-Hodgkin lymphoma, relapsed or refractory B-cell malignancies, maximum tolerated dose, cytokine release syndrome, neurotoxicity, non-relapse mortality, fludarabine and cyclophosphamide conditioning
- MeSH terms
- Adolescent, Adult, Child, Child, Preschool, Chimera, Feasibility Studies, Female, Humans, Infant, Lymphoma, Non-Hodgkin, Male, Receptors, Antigen, T-Cell, T-Lymphocytes, Cohort Studies, Treatment Outcome, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
